Literature DB >> 7799246

Cholinergic neurotransmission, REM sleep and depression.

D Riemann1, F Hohagen, M Bahro, S Lis, G Stadmüller, H Gann, M Berger.   

Abstract

It is known from animal experiments that the regulation of REM and Non-REM sleep is governed by cholinergic and serotonergic/adrenergic neurons in the brain stem. Cholinergic neurons in the gigantocellular field of the tegmentum seem to be responsible for the triggering and maintenance of REM sleep. These findings are of special interest for interpreting abnormalities of REM sleep in depression. Psychiatric sleep research in the last two decades has demonstrated that an early onset of REM sleep and heightened REM density frequently occurs in patients suffering from depression. Extrapolating from animal data on REM sleep regulation, the premature onset of REM sleep in depression may be interpreted as the consequence of a central nervous cholinergic overactivity or muscarinic supersensitivity. In our experimental work we have tested assumptions of the so-called reciprocal interaction model of NonREM and REM sleep by cholinergic/anticholinergic stimulation strategies of sleep in healthy subjects. Furthermore, the impact of cholinergic stimulation on sleep in depression, healthy control subjects and other psychopathological conditions was investigated. These studies demonstrated that the most pronounced REM sleep response to cholinergic stimulation occurred in depression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7799246     DOI: 10.1016/0022-3999(94)90132-5

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  14 in total

Review 1.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 2.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

Review 3.  Sleep, insomnia, and depression.

Authors:  Dieter Riemann; Lukas B Krone; Katharina Wulff; Christoph Nissen
Journal:  Neuropsychopharmacology       Date:  2019-05-09       Impact factor: 7.853

4.  Clinical aspects of Alzheimer's disease in black and white patients.

Authors:  R Hargrave; M Stoeklin; M Haan; B Reed
Journal:  J Natl Med Assoc       Date:  1998-02       Impact factor: 1.798

Review 5.  Galantamine: a review of its use in Alzheimer's disease.

Authors:  L J Scott; K L Goa
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 6.  Sleep and plasticity in schizophrenia.

Authors:  Kate E Sprecher; Fabio Ferrarelli; Ruth M Benca
Journal:  Curr Top Behav Neurosci       Date:  2015

Review 7.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Authors:  Krista L Lanctôt; Nathan Herrmann; Kenneth K Yau; Lyla R Khan; Barbara A Liu; Maysoon M LouLou; Thomas R Einarson
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

Review 8.  Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia.

Authors:  Howard Chertkow; Fadi Massoud; Ziad Nasreddine; Sylvie Belleville; Yves Joanette; Christian Bocti; Valérie Drolet; John Kirk; Morris Freedman; Howard Bergman
Journal:  CMAJ       Date:  2008-05-06       Impact factor: 8.262

9.  Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.

Authors:  D M Cannon; J K Klaver; S K Gandhi; G Solorio; S A Peck; K Erickson; N Akula; J Savitz; W C Eckelman; M L Furey; B J Sahakian; F J McMahon; W C Drevets
Journal:  Mol Psychiatry       Date:  2010-03-30       Impact factor: 15.992

Review 10.  Galantamine for Alzheimer's disease and mild cognitive impairment.

Authors:  C Loy; L Schneider
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.